Home › NDC Lookup › Ingredients › Docosanol › 70677-1255-01
🧴image loading
(from DailyMed)

Cold Sore Fever Blister Treatment Docosanol 100 mg/g Cream — NDC 70677-1255-1 (Billing 70677-1255-01)

by Strategic Sourcing Services LLC · 1 TUBE in 1 PACKAGE / 2 g in 1 TUBE

This is a package of Cold Sore Fever Blister Treatment Docosanol 100 mg/g Cream from Strategic Sourcing Services LLC, marketed since Jan 2024 and currently FDA-listed, this package's marketing is listed to end Dec 2027; retail pharmacies pay about $5.79 per g (NADAC). It is this product's only package size.

NDC 70677-1255-01
🏷️ FDA NDC (as labeled) 70677-1255-1 billing pads the package segment with a zero
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70677-1255-1
Product NDC 70677-1255
11-digit billing NDC 70677125501
NCPDP billing unit GM — per gram (weight)
RxCUI 797534
UNII 9G1OE216XY
UPC 0010939960566
Application # ANDA212385
SPL Set ID 8a6bb379-bc3a-4ad2-9ecd-8fe1870873d8
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-01-14
Marketing end 2027-12-31
Route TOPICAL
Dosage form CREAM
Substance DOCOSANOL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90350022003720
GCN Seq No 047524
GCN 12866
HICL code 021956
Ingredient (HICL) Docosanol
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5V
Therapeutic class — specific (HIC3) Topical Antivirals
AHFS code 84:04.06.00
AHFS class Antivirals (Skin And Mucous Membrane)
FDB label name FT DOCOSANOL 10% CREAM
FDB brand name Docosanol
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 047524
  • GCN: 12866
  • GPI-14 (Medi-Span): 90350022003720
  • HICL (First Databank): 021956
  • AHFS class code: 84:04.06.00
  • RxCUI (RxNorm): 797534
Why two NDCs? The FDA registers this code as 70677-1255-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70677-1255-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antivirals class.

Drug family (ATC) Antivirals
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name FT DOCOSANOL 10% CREAM Ingredient Docosanol
📗 Our plain-language guide HelloPharmacist
  • It treats cold sores, also called fever blisters, on your face or lips. It can shorten healing time and how long tingling, pain, burning and itching last.
  • Start at the very first sign, usually a tingle. Early treatment gives the best results. Wash your hands before and after, then rub it in gently but completely.
  • Adults and children 12 and older use it 5 times a day until the cold sore heals. If your child is under 12, check with a doctor first.
  • It can rarely cause a severe allergic reaction, with hives, facial swelling, wheezing, rash or trouble breathing. If that happens, stop and get medical help right away. Do not use...
📖 Read our full Docosanol guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Docosanol — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Docosanol (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $5.793 $11.59 / 2 g
Medicaid paysCMS SDUD · 12 mo $9.34 $18.68 / 2 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $6.817 $5.793
▼ Down 13% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70677-1255-01 You're viewing this Main listing 1 TUBE in 1 PACKAGE / 2 g in 1 TUBE 2024-01-14 Dec 31, 2027 Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Docosanol 100 mg/g 00536-1427-04 Rugby 1 tube $5.793 — Availability likely —
Docosanol 100 mg/g 00713-0353-02 Cosette 1 tube $5.793 — Availability likely —
Docosanol 100 mg/g 46122-0800-36 Amerisource 1 tube $5.793 — Availability likely —
Docosanol 100 mg/g 51672-1406-02 Sun 2 tubes $5.793 — Availability likely —
Docosanol 100 mg/g 61269-0881-35 H2-Pharma, 2 g $5.793 — Availability likely —
Docosanol 100 mg/g 61269-0989-37 H2-Pharma, 1 bottle $5.793 — Availability likely —
Docosanol 100 mg/g 70000-0672-01 Leader/ 1 tube $5.793 — Availability likely —
Cold Sore Fever Blister Treatment 100 mg/gthis 70677-1255-01 Strategic 1 tube $5.793 — Availability likely —
Docosanol 100 mg/g 62011-0433-01 Strategic 1 tube $5.946 — FDA listed +3%
Abreva 100 mg/g 00135-0200-01 Haleon 2 g — — FDA listed —
Abreva 100 mg/g 00135-0300-01 Haleon 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 00363-6510-07 Walgreens 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 00363-8877-07 Walgreens 2 g — — FDA listed —
Docosanol 100 mg/g 00363-8980-07 Walgreens 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 00363-9220-07 Walgreens 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 00363-9222-07 Walgreens 1 tube — — FDA listed —
Cold Sore Treatment Docosanol 100 mg/g 10157-2124-02 Blistex 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 11673-0769-14 TARGET 2 tubes — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 11673-0846-14 TARGET 2 tubes — — FDA listed —
Docosanol 100 mg/g 21130-0422-07 Safeway, 1 tube — — Discontinued —
Cold Sore Fever Blister Treatment 100 mg/g 21130-0605-07 Safeway, 2 g — — FDA listed —
Docosanol 100 mg/g 21130-0770-07 Safeway, 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 21130-0823-07 Safeway, 1 tube — — FDA listed —
Docosanol 100 mg/g 21922-0023-17 Encube 1 bottle — — FDA listed —
Docosanol 100 mg/g 30142-0286-02 KROGER 1 tube — — FDA listed —
Cold Sore Fever Blister 100 mg/g 30142-0322-07 The 1 tube — — Discontinued —
Cold Sore Fever Blister Treatment 100 mg/g 30142-0869-07 The 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 30142-0981-07 The 1 tube — — FDA listed —
Cold Sore Fever Blister 100 mg/g 37808-0223-07 H 1 tube — — FDA listed —
Cold Sore Treatment 100 mg/g 37808-0229-07 H 1 tube — — FDA listed —
Cold Sore Fever Blister 100 mg/g 37808-0661-07 H 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 37808-0765-07 H 2 g — — FDA listed —
Docosanol 100 mg/g 41163-0724-07 United 1 tube — — FDA listed —
Docosanol 100 mg/g 41250-0867-07 MEIJER, 1 tube — — FDA listed —
Docosanol 100 mg/g 41415-0660-03 Publix 1 tube — — FDA listed —
Docosanol 100 mg/g 46708-0682-01 Alembic 1 tube — — FDA listed —
Docosanol 100 mg/g 49035-0259-35 EQUATE 1 tube — — FDA listed —
Docosanol 100 mg/g 51316-0763-02 CVS 1 tube — — FDA listed —
Docosanol 100 mg/g 55301-0112-07 AAFES/Your 1 tube — — FDA listed —
Docosanol 100 mg/g 55301-0877-07 AAFES/Your 1 tube — — FDA listed —
Docosanol 100 mg/g 55319-0922-07 Family 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 55910-0550-07 Dolgencorp, 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 55910-0859-07 Dolgencorp, 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 55910-0963-07 Dolgencorp, 1 tube — — FDA listed —
Docosanol 100 mg/g 58602-0019-08 Aurohealth 1 tube — — FDA listed —
Cold Sore Treatment 100 mg/g 59726-0112-07 P 1 tube — — FDA listed —
Cold Sore Fever Blister 100 mg/g 59726-0221-07 P 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 59726-0877-07 P 2 g — — FDA listed —
Cold Sore Treatment 100 mg/g 59726-0922-07 P 1 tube — — FDA listed —
Cold Sore Treatment 100 mg/g 59726-0924-07 P 1 tube — — FDA listed —
Docosanol 100 mg/g 62332-0682-01 Alembic 1 tube — — FDA listed —
Docosanol 100 mg/g 63941-0922-07 Best 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 68016-0344-07 Chain 1 tube — — FDA listed —
Docosanol 100 mg/g 70000-0743-01 Leader/ 1 bottle — — FDA listed —
Amazon Basics Docosanol 100 mg/g 72288-0006-01 Amazon.com 1 tube — — FDA listed —
Docosanol 100 mg/g 72476-0492-07 Care 1 tube — — FDA listed —
Docosanol 100 mg/g 72476-0922-07 Care 1 tube — — FDA listed —
Docosanol 100 mg/g 72476-0965-07 Care 1 tube — — FDA listed —
Docosanol 100 mg/g 73581-0004-02 YYBA 2 tubes — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 76162-0818-07 Topco 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 76162-0900-07 Topco 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 79481-0065-07 Meijer 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 79481-9220-07 Meijer 2 tubes — — FDA listed —
Docosanol 100 mg/g 79903-0011-07 WALMART 1 tube — — FDA listed —
Docosanol 100 mg/g 79903-0118-14 WALMART 2 tubes — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 79903-0248-07 WALMART 1 tube — — FDA listed —
Docosanol 100 mg/g 79903-0402-10 WALMART 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 79903-0435-00 WALMART 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 81522-0112-07 FSA 1 tube — — FDA listed —
Cold Sore Treatment 100 mg/g 81522-0922-07 FSA 1 tube — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 81522-0923-07 FSA 1 tube — — FDA listed —
Julie Cold Sore Treatment 100 mg/g 82791-0362-01 Julie 2 g — — FDA listed —
Cold Sore Fever Blister Treatment 100 mg/g 85766-0239-02 Sportpharm 1 tube — — FDA listed —
Docosanol 100 mg/g 84725-0001-01 KLM 1 tube — — FDA listed —
Docosanol 100 mg/g 43598-0044-02 Dr.Reddys' 1 tube — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Jan 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerStrategic Sourcing Services LLC
Application holderP AND L DEVELOPMENT LLC
FDA applicationANDA212385 (ANDA)
Labeler code70677
First marketedJan 2024
Product typeHuman Otc Drug
Portfolio316 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 22 words ▾

Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching

⏱️ Dosage and Administration 58 words ▾

Directions adults and children 12 years or over: wash hands before and after applying cream apply to affected area on the face or lips at the first sign of cold sore/fever blister (tingle). early treatment ensures the best results rub in gently but completely use 5 times a day until healed children under 12 years: ask a doctor

⚠️ Warnings 37 words ▾

Warnings Allergy Alert: This product may cause a severe allergic reaction. Symptoms may include: hives facial swelling wheezing/difficulty shock rash If an allergic reaction occurs, stop use and seek medical help right away. For external use only

🧪 Active Ingredient 4 words ▾

Active ingredient Docosanol 10%

🧪 Inactive Ingredients 15 words ▾

Inactive ingredients benzyl alcohol, light mineral oil, propylene glycol, purified water, sucrose distearate, sucrose stearate

🎯 Purpose 5 words ▾

Purpose Cold sore/fever blister treatment

📄 Do Not Use 13 words ▾

Do not use if you are allergic to any ingredient in this product

📄 When Using This Product 36 words ▾

When using this product apply only to the affected areas do not use in or near the eyes avoid applying directly inside your mouth do not share this product with anyone. This may spread the infection.

📄 Stop Use and Ask a Doctor If 22 words ▾

Stop use and ask a doctor if your cold sore gets worse or the cold sore is not healed within 10 days

📄 Keep Out of Reach of Children 20 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

📄 Questions or Comments 10 words ▾

Questions or comments? Call 1-833-358-6431 Monday-Friday 9am to 7pm EST

📄 Package Label / Principal Display Panel 105 words ▾

Principal Display Panel COMPARE TO ABREVA® ACTIVE INGREDIENT* Docosanol Cream, 10% COLD SORE / FEVER BLISTER TREATMENT Only FDA Approved Medicine to Shorten Healing Time† Cold sore treatment NET WT 2 g (0.07 oz) *This product is not manufactured or distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC, distributor of Abreva®. †Docosanol Cream, 10% contain the only OTC medicine approved by the FDA to shorten healing time and duration of symptoms. RETAIN THIS INSERT FOR FULL PRODUCT USES, DIRECTIONS AND WARNINGS Distributed by: McKesson Corp., via Strategic Sourcing Sevices LLC.

Memphis, TN 38141

Package Label FOSTER & THRIVE Cold Sore Fever Blister Treatment Docosanol 10%

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
394
Units reimbursed last 4 qtrs
781
Gross reimbursed last 4 qtrs
$7.3K
Avg / prescription
$18.51
Avg / unit
$9.3388
Latest quarter Q1 2026
94Rx
Medicaid pays / g
$9.3388
gross reimbursed
vs
NADAC / g
$5.7926
acquisition cost
=
Spread
+$3.5462
+61% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 158 Rx Managed care · 236 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 110 units · 1.1 per 100k residents MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 316 units · 3.4 per 100k residents NJ Massachusetts: no data reported MA California: 291 units · 0.7 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 38 units · 0.8 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: 26 units · 0.8 per 100k residents AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.73.4
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 3.4 /100k
2 Michigan 1.1 /100k
3 Arkansas 0.8 /100k
4 Kentucky 0.8 /100k
5 California 0.7 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
← 70677-1254-01 · Strategic 70677-1256-01 · Strategic →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.